Phase Forward Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Phase Forward's estimated annual revenue is currently $24.1M per year.(i)
  • Phase Forward's estimated revenue per employee is $159,500

Employee Data

  • Phase Forward has 151 Employees.(i)
  • Phase Forward grew their employee count by 0% last year.

Phase Forward's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$75.6M4175%N/AN/A
#2
$38.6M24226%N/AN/A
#3
$277.8M1340-1%$38MN/A
#4
$29M186-35%$78.9MN/A
#5
$763.6M12414%$1.8MN/A
#6
$11.9M82-44%$19.5MN/A
#7
$64.9M358-8%N/AN/A
#8
$64.5M350-46%$130MN/A
#9
$26M16336%N/AN/A
#10
$94.5M51322%$187MN/A
Add Company

What Is Phase Forward?

Phase Forward is a leading provider of integrated data collection and data management solutions for clinical trials and drug safety. Our award-winning technology and global services are designed to enable life sciences companies of all types and sizes to automate and integrate the management of their entire clinical development process – from study initiation and FDA submission through post-marketing studies. Our products and services have been used in over 10,000 clinical trials involving more than 1,000,000 trial study participants at over 280 life sciences companies, medical device firms, regulatory agencies and public health organizations.

keywords:N/A

N/A

Total Funding

151

Number of Employees

$24.1M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phase Forward News

2022-04-19 - Way forward for Project 75(I) and MDL

Project 75(I) is the second part of Phase I of the 30-year submarine building plan, approved by the CCS in Jul 1999, which was to be...

2022-04-17 - Nasal spray to treat anxiety moves forward with global phase ...

VistaGen Therapeutics and AffaMed Therapeutics announced a global phase 3 trial to assess the efficacy, safety and tolerability of a nasal...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.4M15130%N/A
#2
$34.3M1521%N/A
#3
$41.2M154-4%N/A
#4
$39.2M1578%N/A
#5
$41.5M158N/AN/A